Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin

Journal of Immunology

Volumn 175, Issue 6, 2005, Pages 3707-3714

  Nierkens, Stefan ^a,d   Aalbers, Marloes ^a   Bol, Marianne ^a   Bleumink, Rob ^a   Van Kooten, Peter ^b   Boon, Louis ^c   Pieters, Raymond ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c BIOCEROS   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD80 MONOCLONAL ANTIBODY; CD86 ANTIGEN; CD86 MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; MONOCLONAL ANTIBODY; OVALBUMIN; PENICILLAMINE; STREPTOZOCIN; TRINITROPHENYL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; FEMALE; IMMEDIATE TYPE HYPERSENSITIVITY; LUPUS VULGARIS; LYMPH NODE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REPORTER ANTIGEN POPLITEAL LYMPH NODE ASSAY; SIGNAL TRANSDUCTION;

EID: 24744450550     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.6.3707     Document Type: Article

References (43)

1. Adkinson, N. F., Jr., D. Essayan, R. Gruchalla, H. Haggerty, T. Kawabata, J. D. Sandler, L. Updyke, N. H. Shear, and D. Wierda. 2002. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J. Allergy Clin. Immunol. 109: S461-S478.
2. Uetrecht, J. P. 1999. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12: 387-395.
3. Gruchalla, R. S. 2001. Drug metabolism, danger signals, and drug-induced hypersensitivity. J. Allergy Clin. Immunol. 108: 475-488.
4. Pirmohamed, M., D. J. Naisbitt, F. Gordon, and B. K. Park. 2002. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182: 55-63.
5. Seguin, B., and J. Uetrecht. 2003. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 3: 235-242.
6. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252.
7. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
8. Rossini, A. A., M. C. Appel, R. M. Williams, and A. A. Like. 1977. Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes 26: 916-920.
9. Emery, P., and G. Panayi. 1989. Autoimmune reactions to D-penicillamine. In Autoimmunity and toxicology. M. E. Kammüller, N. Bloksma, and W. Seinen, eds. Elsevier Science, Amsterdam, p. 167.
10. Nierkens, S., P. van Helden, M. Bol, R. Bleumink, P. van Kooten, S. Ramdien-Murli, L. Boon, and R. Pieters. 2002. Selective requirement for CD40-CD154 in drug-induced type 1 versus type 2 responses to trinitrophenylovalbumin. J. Immunol. 168: 3747-3754.
11. Khoury, S. J., E. Akalin, A. Chandraker, L. A. Turka, P. S. Linsley, M. H. Sayegh, and W. W. Hancock. 1995. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155: 4521-4524.
12. Lenschow, D. J., K. C. Herold, L. Rhee, B. Patel, A. Koons, H. Y. Qin, E. Fuchs, B. Singh, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5: 285-293.
13. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718.
14. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181: 1145-1155.
15. Gleichmann, H. 1981. Studies on the mechanism of drug sensitization: T-cell-dependent popliteal lymph node reaction to diphenylhydantoin. Clin. Immunol. Immunopathol. 18: 203-211.
16. Kammuller, M. E., C. Thomas, J. M. De Bakker, N. Bloksma, and W. Seinen. 1989. The popliteal lymph node assay in mice to screen for the immune disregulating potential of chemicals-a preliminary study. Int. J. Immunopharmacol. 11: 293-300.
17. Albers, R., A. Broeders, A. van der Pijl, W. Seinen, and R. Pieters. 1997. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol. Appl. Pharmacol. 143: 102-109.
18. 2. Eur. J. Immunol. 28: 1233-1242.
19. Van Oosterhout, A. J., C. L. Hofstra, R. Shields, B. Chan, I. Van Ark, P. M. Jardieu, and F. P. Nijkamp. 1997. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 17: 386-392.
20. Schielen, P., W. van Rodijnen, J. Tekstra, R. Albers, and W. Seinen. 1995. Quantification of natural antibody producing B cells in rats by an improved ELISPOT technique using the polyvinylidene difluoride membrane as the solid support. J. Immunol. Methods 188: 33-41.
21. + T cells. J. Immunol. 157: 3250-3259.
22. Chang, T. T., C. Jabs, R. A. Sobel, V. K. Kuchroo, and A. H. Sharpe. 1999. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med. 190: 733-740.
23. Webb, L. M., M. J. Walmsley, and M. Feldmann. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26: 2320-2328.
24. Subauste, C. S., R. de Waal Malefyt, and F. Fuh. 1998. Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen. J. Immunol. 160: 1831-1840.
25. Khattri, R., J. A. Auger, M. D. Griffin, A. H. Sharpe, and J. A. Bluestone. 1999. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J. Immunol. 162: 5784-5791.
26. Pioli, C., L. Gatta, V. Ubaldi, and G. Doria. 2000. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J. Immunol. 165: 5530-5536.
27. Greene, J. L., G. M. Leytze, J. Emswiler, R. Peach, J. Bajorath, W. Cosand, and P. S. Linsley. 1996. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271: 26762-26771.
28. Ikemizu, S., R. J. Gilbert, J. A. Fennelly, A. V. Collins, K. Harlos, E. Y. Jones, D. I. Stuart, and S. J. Davis. 2000. Structure and dimerization of a soluble form of B7-1. Immunity 12: 51-60.
29. Zhang, X., J. C. Schwartz, S. C. Almo, and S. G. Nathenson. 2003. Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling. Proc. Natl. Acad. Sci. USA 100: 2586-2591.
30. Mueller, D. L. 2000. T cells: a proliferation of costimulatory molecules. Curr Biol. 10: R227-R230.
31. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569.
32. Gruchalla, R. S. 2003. 10. Drug allergy. J. Allergy Clin. Immunol. 111: S548-S559.
33. Hizawa, N., E. Yamaguchi, E. Jinushi, S. Konno, Y. Kawakami, and M. Nishimura. 2001. Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B. J. Allergy Clin. Immunol. 108: 74-79.
34. Lee, S. Y., Y. H. Lee, C. Shin, J. J. Shim, K. H. Kang, S. H. Yoo, and K. H. In. 2002. Association of asthma severity and bronchial hyperresponsiveness with a polymorphism in the cytotoxic T-lymphocyte antigen-4 gene. Chest 122: 171-176.
35. Ueda, H., J. M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D. B. Rainbow, K. M. Hunter, A. N. Smith, G. Di Genova, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
36. Herold, K. C., V. Vezys, A. Koons, D. Lenschow, C. Thompson, and J. A. Bluestone. 1997. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J. Immunol. 158: 984-991.
37. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1: 793-801.
38. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101.
39. Guillot, C., S. Menoret, C. Guillonneau, C. Braudeau, M. G. Castro, P. Lowenstein, and I. Anegon. 2003. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood 101: 3325-3333.
40. + T cells in vitro. J. Exp. Med. 183: 2247-2257.
41. Razi-Wolf, Z., F. Galvin, G. Gray, and H. Reiser. 1993. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. Proc. Natl. Acad. Sci. USA 90: 11182-11186.
42. Razi-Wolf, Z., L. D. Falo, Jr., and H. Reiser. 1994. Expression and function of the costimulatory molecule B7 on murine Langerhans cells: evidence for an alternative CTLA-4 ligand. Eur. J. Immunol. 24: 805-811.
43. S. Nierkens, M. Aalbers, R. Blevmink, L. Boon, and R. Pieters. Drug-induced type-1 and type-2 immune responses are characterized by distinct profiles of cell kinetics, cytokine production, and expression of costimulatory molecules in the popliteal lymph node assay. J. Immunotoxicol. In press.